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Since their characterization as conserved modules that regulate progression
through the eukaryotic cell cycle, cyclin-dependent protein kinases (CDKs)
in higher eukaryotic cells are now also emerging as significant regulators
of transcription, metabolism and cell differentiation. The cyclins, though
originally characterized as CDK partners, also have CDK-independent
roles that include the regulation of DNA damage repair and transcriptional
programmes that direct cell differentiation, apoptosis and metabolic
flux. This review compares the structures of the members of the CDK and
cyclin families determined by X-ray crystallography, and considers what
mechanistic insights they provide to guide functional studies and dis-
tinguish CDK- and cyclin-specific activities. Aberrant CDK activity is a
hallmark of a number of diseases, and structural studies can provide
important insights to identify novel routes to therapy.1. Introduction
Members of the cyclin-dependent protein kinase (CDK) family were originally
characterized as serine/threonine-specific protein kinases activated by the
expression of cyclin partners to drive the eukaryotic cell cycle [1]. Within the
CMGC branch of the kinome, 20 proteins are now considered to be members
of the CDK family that can be grouped into different phylogenetic sub-branches
(see [2] for criteria for inclusion, illustrated and updated in [3]). In overview,
in addition to those CDKs that regulate the cell cycle (CDKs 1, 2, 4 and 6), a
substantial sub-branch of the family (CDKs 7, 8, 9, 12 and 13) regulates tran-
scription through phosphorylation of the heptad repeats that comprise the
C-terminal tail of RNA polymerase II (CTD) [4]. CDK7 is unusual in that it
also indirectly regulates the cell cycle by activating CDKs 1, 2, 4 and 6 [5,6].
CDK3 phosphorylates retinoblastoma protein (pRB) to promote the transition
from quiescence (G0) into G1 [7].
Other CDKs (CDKs 5, 10, 11, 14–18 and 20) have more diverse, CDK-
unique functions that are frequently tissue-specific [8]. For example, CDK5
was one of the first CDKs to be characterized in non-cycling cells [9]. CDK10
is implicated in regulating gene transcription, but not through RNA pol II
phosphorylation. It phosphorylates diverse substrates including the ETS2 onco-
protein and the protein kinase PKN2, and mutations in its cognate cyclin, cyclin
M, result in STAR syndrome, a human developmental disorder [10,11]. CDK10
mutant and knockout mice also show growth and developmental delays [12].
CDK11–cyclin L complexes regulate RNA splicing, studied, for example, in
the context of human immunodeficiency virus (HIV) transcript processing
[13]. However, insights into these CDK–cyclin interactions are limited by the
lack of structures for CDK10- and CDK11-containing complexes.
To partner the CDKs in humans, approximately 30 proteins are classified as
cyclins [3,8]. The cyclins share very little sequence homology, but are structu-
rally defined by the presence of either one or two copies of the cyclin box
fold (CBF) [3,14]. The structures of monomeric CDK2 and cyclin A and of
Table 1. CDK-containing complexes deosited in the Protein Data Bank (PDB).
CDK partnersa
CDK1 cyclin B, Cks1, Cks2
CDK2 cyclin A/B/E, KAP, Cks1, p27KIP1, Spy-1
CDK4/6 cyclin D (structurally CDK4–cyclin D), viral cyclin
(CDK6), p16INK4A (CDK6), p19INK4D (CDK6),
HSP90–Cdc37 (CDK4), p18INK4C–cyclin K (CDK6)
CDK5 p25
CDK8 cyclin C
CDK9 cyclin T, Tat, AFF4, TAR
CDK12 cyclin K
CDK13 cyclin K
aPartner proteins included in the table are those for which CDK-complex
structures have been deposited in the Protein Data Bank.
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taken to be a model for the regulation of the CDK family
by cyclin binding and phosphorylation [15]. However, sub-
sequent studies have shown that even closely related CDKs
have distinct structural and sequence peculiarities. These
differences translate into diverse substrate preferences and
modes of regulation. CDK activity is wired into cell-type-
specific signalling networks with the result that, taken
together, knockout mice studies reveal both the redundancy
inherent within the cell cycle CDKs, but also their tissue-
specific activities ([16], CDK1; [17,18], CDK2; [19,20], CDK4;
and [21,22], CDK6).
Dysregulation of CDK activity, either through activation of
proteins that promoteCDKactivityor inactivation of oncogene-
induced senescence pathways, is a common occurrence in
various cancers [23–27]. Identifying and characterizing those
cancers that require specific CDK activities for proliferation
will provide the mechanistic understanding to better employ
CDK-selective inhibitors. However, the importance of CDK
activity to cancer initiation, growth and differentiation is
further complicated by the emerging cell-cycle-independent
roles of individual CDKs and cyclins in mammalian cells
that are, respectively, cyclin and CDK partner-independent
[28–30].
In this review, we compare and contrast the various
monomeric CDK, CDK–cyclin and CDK-containing assem-
blies for which structures have been determined, and
discuss how they might help to elucidate the different mech-
anisms that regulate CDK activity. Proteomic studies are
identifying multiple proteins that bind to CDKs and cyclins
that apparently do not share sequence features with proteins
for which structures bound to CDKs or cyclins are available
(table 1). A comparison of the structures of CDK–cyclin com-
plexes reveals how the CDK and cyclin partners can differ in
their relative disposition and the alternative surfaces that can
be exploited to recognize CDK substrates and regulators. The
extent to which protein interaction sites are conserved and
recycled within the CDK and cyclin families is yet to be
fully explored, but will be reviewed here. The kinetic and cat-
alytic mechanism of protein kinases including CDK2 was
reviewed in 2012 [31]. The structures of CDK–cyclin com-
plexes bound to ATP-competitive inhibitors have also been
reviewed recently [32], and these will only be discussed in
so far as they give insights into functionally significant
conformations.2. Relating structure and function
2.1. The inactive monomeric CDK fold
CDKs vary in the lengths of N- and C-terminal sequences
that bookend the conserved, central protein kinase domain
[8] (figure 1). Overall, the structures of cyclin-free CDK1
([34], PDB 4YC6), CDK2 ([35], PDB 1HCK), CDK6 ([36], e.g.
PDB 5L2S), CDK7 ([37], PDB 1UA2) and CDK16 ([38], PDB
5G6 V) superimpose very well. For example, monomeric
CDK2 and CDK7 overlay with an r.m.s.d. (root-mean-
square deviation) of 1.49 A˚ over 262 equivalent Ca atoms.
They share conserved structural features that ensure they
are catalytically inactive (figure 2a). The start of the activation
loop (defined as the sequence between the conserved DFG
and APE motifs, residues 145–172 in CDK2) adopts a shorta-helical conformation (aL12) that blocks the C-helix from
swinging in to reshape the back of the active-site cleft. A
characteristic of the glycine-rich (residues 12–16 in CDK2
that encodes the conserved GXGXXG motif ) and activation
loops is their relative mobility. As a result, differences
between cyclin-free CDK structures are most evident
around the active site (figure 2b,c). Accompanying these
changes are more subtle differences in the relative disposi-
tions of the N- and C-terminal lobes that lead to other
conserved residues within the catalytic sites adopting
positions that are incompatible with catalysis (figure 2b).
The classical model of CDK activation exemplified by
CDK2–cyclin A is not applicable to the CDK5-related sub-
branch of the CDK family of which CDK16 is a member
[3]. There are several emerging unusual features of CDK16
activation that would benefit from structural characterization.
A CDK16 feature that it shares with CDKs 14, 15, 17 and 18 is
an extended N-terminal regulatory region before the start of
the kinase domain. This sequence is important for CDK16
association with its cognate cyclin, cyclin Y or cyclin Y-like
1 [3,41–43]. In addition, stable association of cyclin Y with
either CDK14 [44] or CDK16 [45] requires cyclin Y phos-
phorylation and binding to 14-3-3, suggesting that a
classical bidentate 14-3-3–ligand interaction [46] may help
to organize cyclin Y to bind to its cognate CDK partner.2.2. CDK2–cyclin A activation
CDK2 partners cyclin E during late G1 and is subsequently
bound to cyclin A during S-phase for DNA replication [1].
A series of structures of CDK2 bound to cyclin A provided
snapshots of the structural changes that accompany cyclin
binding and phosphorylation of the CDK2 activation loop
[39,47,48] (figure 3a). Subsequent studies that have interro-
gated the kinetics of CDK2 activation in a cellular context
have demonstrated that CDK-activating kinase (CAK, a com-
plex of CDK7 and cyclin H in humans) is active against CDK2
(i.e. through phosphorylation of CDK2 T160), which is then
proposed to bind to cyclin A [52]. This result suggests a
model in which flexibility around T160 is required for
CDK2 to be recognized by CAK and that the adoption of
an ordered activation loop conformation accompanies
HsCDK1    182 STPVDIWSIGTIFAELAT-KKPLFHGDS---------EIDQLFRIFRALGTPNNEVWPEV 
HsCDK2    181 STAVDIWSLGCIFAEMVT-RRALFPGDS---------EIDQLFRIFRTLGTPDEVVWPGV 
HsCDK3    181 TTAVDIWSIGCIFAEMVT-RKALFPGDS---------EIDQLFRIFRMLGTPSEDTWPGV 
HsCDK4    192 ATPVDMWSVGCIFAEMFR-RKPLFCGNS---------EADQLGKIFDLIGLPPEDDWPRD 
HsCDK5    180 STSIDMWSAGCIFAELANAGRPLFPGND---------VDDQLKRIFRLLGTPTEEQWPSM 
HsCDK6    197 ATPVDLWSVGCIFAEMFR-RKPLFRGSS---------DVDQLGKILDVIGLPGEEDWPRD 
HsCDK7    191 GVGVDMWAVGCILAELLL-RVPFLPGDS---------DLDQLTRIFETLGTPTEEQWPDM 
HsCDK8    212 TKAIDIWAIGCIFAELLT-SEPIFHCRQEDIKTSNPYHHDQLDRIFNVMGFPADKDWEDI 
HsCDK9    207 GPPIDLWGAGCIMAEMWT-RSPIMQGNT---------EQHQLALISQLCGSITPEVWPNV 
HsCDK10   217 TTSIDMWAVGCILAELLA-HRPLLPGTS---------EIHQIDLIVQLLGTPSENIWPGF 
HsCDK11A  604 STAVDMWSVGCIFGELLT-QKPLFPGNS---------EIDQINKVFKELGTPSEKIWPGY 
HsCDK11B  616 STAVDMWSVGCIFGELLT-QKPLFPGKS---------EIDQINKVFKDLGTPSEKIWPGY 
HsCDK12   914 TPAIDVWSCGCILGELFT-KKPIFQANL---------ELAQLELISRLCGSPCPAVWPDV 
HsCDK13   892 TPAIDVWSCGCILGELFT-KKPIFQANQ---------ELAQLELISRICGSPCPAVWPDV 
HsCDK14   310 STCLDMWGVGCIFVEMIQ-GVAAFPGMKD--------IQDQLERIFLVLGTPNEDTWPGV 
HsCDK15   278 SSELDIWGAGCIFIEMFQ-GQPLFPGVSN--------ILEQLEKIWEVLGVPTEDTWPGV 
HsCDK16   340 STQIDMWGVGCIFYEMAT-GRPLFPGST---------VEEQLHFIFRILGTPTEETWPGI 
HsCDK17   367 STQIDMWGVGCIFFEMAS-GRPLFPGST---------VEDELHLIFRLLGTPSQETWPGI 
HsCDK18   317 STPIDMWGVGCIHYEMAT-GRPLFPGST---------VKEELHLIFRLLGTPTEETWPGV 
HsCDK19   212 TKAIDIWAIGCIFAELLT-SEPIFHCRQEDIKTSNPFHHDQLDRIFSVMGFPADKDWEDI 
HsCDK20   182 DQGVDLWSVGCIMGELLN-GSPLFPGKN---------DIEQLCYVLRILGTPNPQVWPEL 
HsCDK1    232 ESLQDYKNT-FPK----WKPGSLASHV--KNLD--ENGLDLLSKMLIYDPAKRISGKMAL 
HsCDK2    231 TSMPDYKPS-FPK----WARQDFSKVV--PPLD--EDGRSLLSQMLHYDPNKRISAKAAL 
HsCDK3    231 TQLPDYKGS-FPK----WTRKGLEEIV--PNLE--PEGRDLLMQLLQYDPSQRITAKTAL 
HsCDK4    242 VSLPRG---AFPP----RGPRPVQSVV--PEME--ESGAQLLLEMLTFNPHKRISAFRAL 
HsCDK5    231 TKLPDYKPY-PMY----PATTSLVNVV--PKLN--ATGRDLLQNLLKCNPVQRISAEEAL 
HsCDK6    247 VALPRQ---AFHS----KSAQPIEKFV--TDID--ELGKDLLLKCLTFNPAKRISAYSAL 
HsCDK7    241 CSLPDYVTF--KS----FPGIPLHHIF--SAAG--DDLLDLIQGLFLFNPCARITATQAL 
HsCDK8    271 KKMPEHSTLMKDFRRNTYTNCSLIKYMEKHKVKPDSKAFHLLQKLLTMDPIKRITSEQAM 
HsCDK9    257 DNYELYEKLELVK----GQKRKVKDRL--KAYVRDPYALDLIDKLLVLDPAQRIDSDDAL 
HsCDK10   267 SKLPLVGQYSLRK----QPYNNLKHKF--P-WL-SEAGLRLLHFLFMYDPKKRATAGDCL 
HsCDK11A  654 SELPVVKKMTFSE----HPYNNLRKRF--GALL-SDQGFDLMNKFLTYFPGRRISAEDGL 
HsCDK11B  666 SELPAVKKMTFSE----HPYNNLRKRF--GALL-SDQGFDLMNKFLTYFPGRRISAEDGL 
HsCDK12   964 IKLPYFNTMKPKK----QYRRRLREEF--SFIP--SAALDLLDHMLTLDPSKRCTAEQTL 
HsCDK13   942 IKLPYFNTMKPKK----QYRRKLREEF--VFIP--AAALDLFDYMLALDPSKRCTAEQAL 
HsCDK14   361 HSLPHFKPERFTL----YSSKNLRQAW--NKLSYVNHAEDLASKLLQCSPKNRLSAQAAL 
HsCDK15   329 SKLPNYNPEWFPL----PTPRSLHVVW--NRLGRVPEAEDLASQMLKGFPRDRVSAQEAL 
HsCDK16   390 LSNEEFKTYNYPK----YRAEALLSHA--PRLD--SDGADLLTKLLQFEGRNRISAEDAM 
HsCDK17   417 SSNEEFKNYNFPK----YKPQPLINHA--PRLD--SEGIELITKFLQYESKKRVSAEEAM 
HsCDK18   367 TAFSEFRTYSFPC----YLPQPLINHA--PRLD--TDGIHLLSSLLLYESKSRMSAEAAL 
HsCDK19   271 RKMPEYPTLQKDFRRTTYANSSLIKYMEKHKVKPDSKVFLLLQKLLTMDPTKRITSEQAL 
HsCDK20   232 TELPDYNKISFKE----QVPMPLEEVL--PDVS—PQALDLLGQFLLYPPHQRIAASKAL 
HsCDK1    283 NHPYFNDLDNQIKKM--------------------------------------------- 
HsCDK2    282 AHPFFQDVTKPVPHLRL------------------------------------------- 
HsCDK3    282 AHPYFSSPE-PSPAARQ----YV-----LQRFR---------H----------------- 
HsCDK4    291 QHSYLHKDEGNPE----------------------------------------------- 
HsCDK5    282 QHPYFSDFCPP------------------------------------------------- 
HsCDK6    296 SHPYFQDLERCKENLDS----HLPPSQNTSELN---------TA---------------- 
HsCDK7    291 KMKYFSNRPGPTPGCQL----PRPNCP-VETLK---------EQSNPALA--I----KR- 
HsCDK8    331 QDPYFLEDPLPTSDVFAGCQIPYPKREFLTEEEPDDKGDKKNQQQQQGNNH--------- 
HsCDK9    311 NHDFFWSDPMPSDLKGM----LSTHLTSMFEYL--A--PPRRKGSQITQ----------- 
HsCDK10   319 ESSYFKEKPLPCEP--E----LMPTFPHHRNKR--A--APA-----TSEG---------- 
HsCDK11A  707 KHEYFRETPLPIDP--S----MFPTWPAKSEQQ--R--VKRGTSPRPPEG---------- 
HsCDK11B  719 KHEYFRETPLPIDP--S----MFPTWPAKSEQQ--R--VKRGTSPRPPEG---------- 
HsCDK12  1016 QSDFLKDVELSKMAPPD-----LPHWQDCHELW--S--KKRRRQRQSGVVVEEPPPSKTS 
HsCDK13   994 QCEFLRDVEPSKMPPPD-----LPLWQDCHELW--S--KKRRRQKQMGMTDDVSTIKAP- 
HsCDK14   415 SHEYFSDLPPRLWELTD----MSSIFT-VPNVR---------LQPEAGES---------- 
HsCDK15   383 VHDYFSALPSQLYQLPD----EESLFT-VSGVR---------LKPEMCDL---------- 
HsCDK16   442 KHPFFLSLGERIHKLPD----TTSIFA-LKEIQ---------LQKEASLR---------- 
HsCDK17   469 KHVYFRSLGPRIHALPE----SVSIFS-LKEIQ---------LQKDPGFR---------- 
HsCDK18   419 SHSYFRSLGERVHQLED----TASIFS-LKEIQ---------LQKDPGYR---------- 
HsCDK19   331 QDPYFQEDPLPTLDVFAGCQIPYPKREFLNEDDPEEKGDKNQQQQQNQHQQPTAPPQQ-- 
HsCDK20   284 LHQYFFTAPLPAHPSEL----PIPQRL--GGPA---------PKAHPGPPHIH----DF- 
aC-helix
hinge
  glycine-rich loop
activation loop
b1 b2 b3 b3
HsCDK1      1 --------------------------MEDYTKIEKIGEGTYGVVYKGRHKT-TGQ-VVAM 
HsCDK2      1 --------------------------MENFQKVEKIGEGTYGVVYKARNKL-TGE-VVAL 
HsCDK3      1 --------------------------MDMFQKVEKIGEGTYGVVYKAKNRE-TGQ-LVAL 
HsCDK4      1 ------------------------MATSRYEPVAEIGVGAYGTVYKARDPH-SGH-FVAL 
HsCDK5      1 --------------------------MQKYEKLEKIGEGTYGTVFKAKNRE-THE-IVAL 
HsCDK6      1 ----------------M-EKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGR-FVAL 
HsCDK7      1 ----------------M-ALDV-KSRAKRYEKLDFLGEGQFATVYKARDKN-TNQ-IVAI 
HsCDK8      3 YDFKVKLSSERER----------VEDLFEYE-GCKVGRGTYGHVYKAKRKDGKDDKDYAL 
HsCDK9      1 -------MAKQYDS----VECPFCDEVSKYEKLAKIGQGTFGEVFKARHRK-TGQ-KVAL 
HsCDK10    16 IR-KEGFFTVPP----E-HRLGRCRSVKEFEKLNRIGEGTYGIVYRARDTQ-TDE-IVAL 
HsCDK11A  404 IELKQEL--PKY----L-PALQGCRSVEEFQCLNRIEEGTYGVVYRAKDKK-TDE-IVAL 
HsCDK11B  416 IELKQEL--PKY----L-PALQGCRSVEEFQCLNRIEEGTYGVVYRAKDKK-TDE-IVAL 
HsCDK12   698 YKKRPKICCPRYGERRQTESDWGKRCVDKFDIIGIIGEGTYGQVYKAKDKD-TGE-LVAL 
HsCDK13   676 SKRRPKICGPRYGETKEKDIDWGKRCVDKFDIIGIIGEGTYGQVYKARDKD-TGE-MVAL 
HsCDK14 117 ---------RHSSPSSP-TSPK-FGKADSYEKLEKLGEGSYATVYKGKSKV-NGK-LVAL
HsCDK15    87 -----------QGFQWR-KSLP-FGAASSYLNLEKLGEGSYATVYKGISRI-NGQ-LVAL 
HsCDK16   147 ---------RRLRRVSL-SEIG-FGKLETYIKLDKLGEGTYATVYKGKSKL-TDN-LVAL 
HsCDK17   174 ---------RRSRRASL-SEIG-FGKMETYIKLEKLGEGTYATVYKGRSKL-TEN-LVAL 
HsCDK18   124 ---------RMSRRASL-SDIG-FGKLETYVKLDKLGEGTYATVFKGRSKL-TEN-LVAL 
HsCDK19     3 YDFKAKLAAERER----------VEDLFEYE-GCKVGRGTYGHVYKARRKDGKDEKEYAL 
HsCDK20     1 --------------------------MDQYCILGRIGEGAHGIVFKAKHVE-TGE-IVAL 
HsCDK1     33 KKIRLESE---EEGVPSTAIREISLLKE---LRHPN-IVSLQDVLMQ----------DSR 
HsCDK2     33 KKIRLDTE---TEGVPSTAIREISLLKE---LNHPN-IVKLLDVIHT----------ENK 
HsCDK3     33 KKIRLDLE---MEGVPSTAIREISLLKE---LKHPN-IVRLLDVVHN----------ERK 
HsCDK4     35 KSVRVPNGGGGGGGLPISTVREVALLRRLEAFEHPN-VVRLMDVCATSR-----TDREIK 
HsCDK5     33 KRVRLDDD---DEGVPSSALREICLLKE---LKHKN-IVRLHDVLHS----------DKK 
HsCDK6     43 KRVRVQTG---EEGMPLSTIREVAVLRHLETFEHPN-VVRLFDVCTVSR-----TDRETK 
HsCDK7     41 KKIKLGHRSEAKDGINRTALREIKLLQE---LSHPN-IIGLLDAFGH----------KSN 
HsCDK8     52 KQI----E---GTGISMSACREIALLRE---LKHPN-VISLQKVFLSHA--------DRK 
HsCDK9     48 KKVLMENE---KEGFPITALREIKILQL---LKHEN-VVNLIEICRTK--ASPYNRCKGS 
HsCDK10    68 KKVRMDKE---KDGIPISSLREITLLLR---LRHPN-IVELKEVVVGNH--------LES 
HsCDK11A  455 KRLKMEKE---KEGFPITSLREINTILK---AQHPN-IVTVREIVVGSN--------MDK 
HsCDK11B  467 KRLKMEKE---KEGFPITSLREINTILK---AQHPN-IVTVREIVVGSN--------MDK 
HsCDK12   756 KKVRLDNE---KEGFPITAIREIKILRQ---LIHRS-VVNMKEIVTDKQDALDFKKDKGA 
HsCDK13   734 KKVRLDNE---KEGFPITAIREIKILRQ---LTHQS-IINMKEIVTDKEDALDFKKDKGA 
HsCDK14   164 KVIRLQE----EEGTPFTAIREASLLKG---LKHAN-IVLLHDIIHT----------KET 
HsCDK15   132 KVISMNA----EEGVPFTAIREASLLKG---LKHAN-IVLLHDIIHT----------KET 
HsCDK16   194 KEIRLEH----EEGAPCTAIREVSLLKD---LKHAN-IVTLHDIIHT----------EKS 
HsCDK17   221 KEIRLEH----EEGAPCTAIREVSLLKD---LKHAN-IVTLHDIVHT----------DKS 
HsCDK18   171 KEIRLEH----EEGAPCTAIREVSLLKN---LKHAN-IVTLHDLIHT----------DRS 
HsCDK19    52 KQI----E---GTGISMSACREIALLRE---LKHPN-VIALQKVFLSHS--------DRK 
HsCDK20    33 KKVALRRL---EDGFPNQALREIKALQE---MEDNQYVVQLKAVFPH----------GGG 
HsCDK1     76 LYLIFEFLSMDLKKYLDSIP------PGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDL 
HsCDK2     76 LYLVFEFLHQDLKKFMDASA-------LTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDL 
HsCDK3     76 LYLVFEFLSQDLKKYMDSTP-------GSELPLHLIKSYLFQLLQGVSFCHSHRVIHRDL 
HsCDK4     89 VTLVFEHVDQDLRTYLDKAP-------PPGLPAETIKDLMRQFLRGLDFLHANCIVHRDL 
HsCDK5     76 LTLVFEFCDQDLKKYFDSCN--------GDLDPEIVKSFLFQLLKGLGFCHSRNVLHRDL 
HsCDK6     94 LTLVFEHVDQDLTTYLDKVP-------EPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDL 
HsCDK7     87 ISLVFDFMETDLEVIIKDNS--------LVLTPSHIKAYMLMTLQGLEYLHQHWILHRDL 
HsCDK8     93 VWLLFDYAEHDLWHIIKFHRASKANKKPVQLPRGMVKSLLYQILDGIHYLHANWVLHRDL 
HsCDK9     99 IYLVFDFCEHDLAGLLSNVL--------VKFTLSEIKRVMQMLLNGLYYIHRNKILHRDM 
HsCDK10   113 IFLVMGYCEQDLASLLENMP--------TPFSEAQVKCIVLQVLRGLQYLHRNFIIHRDL 
HsCDK11A  500 IYIVMNYVEHDLKSLMETMK--------QPFLPGEVKTLMIQLLRGVKHLHDNWILHRDL 
HsCDK11B  512 IYIVMNYVEHDLKSLMETMK--------QPFLPGEVKTLMIQLLRGVKHLHDNWILHRDL 
HsCDK12   809 FYLVFEYMDHDLMGLLESGL--------VHFSEDHIKSFMKQLMEGLEYCHKKNFLHRDI 
HsCDK13   787 FYLVFEYMDHDLMGLLESGL--------VHFNENHIKSFMRQLMEGLDYCHKKNFLHRDI 
HsCDK14   206 LTLVFEYVHTDLCQYMDKHP--------GGLHPDNVKLFLFQLLRGLSYIHQRYILHRDL 
HsCDK15   174 LTFVFEYMHTDLAQYMSQHP--------GGLHPHNVRLFMFQLLRGLAYIHHQHVLHRDL 
HsCDK16   236 LTLVFEYLDKDLKQYLDDCG--------NIINMHNVKLFLFQLLRGLAYCHRQKVLHRDL 
HsCDK17   263 LTLVFEYLDKDLKQYMDDCG--------NIMSMHNVKLFLYQILRGLAYCHRRKVLHRDL 
HsCDK18   213 LTLVFEYLDSDLKQYLDHCG--------NLMSMHNVKIFMFQLLRGLAYCHHRKILHRDL 
HsCDK19    93 VWLLFDYAEHDLWHIIKFHRASKANKKPMQLPRSMVKSLLYQILDGIHYLHANWVLHRDL 
HsCDK20    77 FVLAFEFMLSDLAEVVRHAQ--------RPLAQAQVKSYLQMLLKGVAFCHANNIVHRDL 
HsCDK1    130 KPQNLLID----DKGTIKLADFGLARAFGI-P---IRVYTHEVVTLWYRSPEVLLGSARY 
HsCDK2    129 KPQNLLIN----TEGAIKLADFGLARAFGV-P---VRTYTHEVVTLWYRAPEILLGCKYY 
HsCDK3    129 KPQNLLIN----ELGAIKLADFGLARAFGV-P---LRTYTHEVVTLWYRAPEILLGSKFY 
HsCDK4    142 KPENILVT----SGGTVKLADFGLARIYSY-----QMALTPVVVTLWYRAPEVLLQS-TY 
HsCDK5    128 KPQNLLIN----RNGELKLADFGLARAFGI-P---VRCYSAEVVTLWYRPPDVLFGAKLY 
HsCDK6    147 KPQNILVT----SSGQIKLADFGLARIYSF-----QMALTSVVVTLWYRAPEVLLQS-SY 
HsCDK7    139 KPNNLLLD----ENGVLKLADFGLAKSFGS-P---NRAYTHQVVTRWYRAPELLFGARMY 
HsCDK8    153 KPANILVMGEGPERGRVKIADMGFARLFNS-PLKPLADLDPVVVTFWYRAPELLLGARHY 
HsCDK9    151 KAANVLIT----RDGVLKLADFGLARAFSLAKNSQPNRYTNRVVTLWYRPPELLLGERDY 
HsCDK10   165 KVSNLLMT----DKGCVKTADFGLARAYGV-P---VKPMTPKVVTLWYRAPELLLGTTTQ 
HsCDK11A  552 KTSNLLLS----HAGILKVGDFGLAREYGS-P---LKAYTPVVVTQWYRAPELLLGAKEY 
HsCDK11B  564 KTSNLLLS----HAGILKVGDFGLAREYGS-P---LKAYTPVVVTLWYRAPELLLGAKEY 
HsCDK12   861 KCSNILLN----NSGQIKLADFGLARLYNSEE---SRPYTNKVITLWYRPPELLLGEERY 
HsCDK13   839 KCSNILLN----NRGQIKLADFGLARLYSSEE---SRPYTNKVITLWYRPPELLLGEERY 
HsCDK14   258 KPQNLLIS----DTGELKLADFGLARAKSV-P---SHTYSNEVVTLWYRPPDVLLGSTEY 
HsCDK15   226 KPQNLLIS----HLGELKLADFGLARAKSI-P---SQTYSSEVVTLWYRPPDALLGATEY 
HsCDK16   288 KPQNLLIN----ERGELKLADFGLARAKSI-P---TKTYSNEVVTLWYRPPDILLGSTDY 
HsCDK17   315 KPQNLLIN----EKGELKLADFGLARAKSV-P---TKTYSNEVVTLWYRPPDVLLGSSEY 
HsCDK18   265 KPQNLLIN----ERGELKLADFGLARAKSV-P---TKTYSNEVVTLWYRPPDVLLGSTEY 
HsCDK19   153 KPANILVMGEGPERGRVKIADMGFARLFNS-PLKPLADLDPVVVTFWYRAPELLLGARHY 
HsCDK20   129 KPANLLIS----ASGQLKIADFGLARVFSPDG---SRLYTHQVATRWYRAPELLYGARQY 
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Figure 1. Sequence alignment of the human CDK family. Greyscale shading denotes the extent of sequence conservation calculated from UniProt sequences using
CLUSTAL OMEGA [33] and exported into EXPASY BOXSHADE. Structural features described in the text are named and highlighted in colour above the alignment and located
on the fold of CDK1 (extracted from the CDK1–Cks1 complex, PDB code: 4YC6). UniProt codes used: CDK1 (P06493), CDK2 (P24941), CDK3 (Q00526), CDK4 (P11802),
CDK5 (Q00535), CDK6 (Q00534), CDK7 (P50613), CDK8 (P49336), CDK9 (P50750), CDK10 (Q15131), CDK11A (Q9UQ88), CDK11B (P21127), CDK12 (Q9NYV4), CDK13
(Q14004), CDK14 (O94921), CDK15 (Q96Q40), CDK16 (Q00536), CDK17 (Q00537), CDK18 (Q07002), CDK19 (Q9BWU1), CDK20 (Q8IZL9). CDK11A and CDK11B result
from a gene duplication and are almost identical (97.5%).
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Figure 2. The monomeric CDK fold. (a) Structure of monomeric CDK2. The CDK kinase fold, as first exemplified by monomeric CDK2 ([39], PDB 1HCK), is composed
of a smaller N-terminal lobe that is predominantly a twisted anti-parallel b-sheet linked via a flexible hinge sequence to a larger C-terminal lobe dominated in
structure by a-helices (light blue ribbon). Structural features are highlighted: glycine-rich loop (sequence GXGXXG, cyan), aC-helix (residues 45–55, purple), hinge
(residues 80–84, yellow), activation loop (residues 145–172, red). The location of T160 is marked. (b) The monomeric CDK fold is conserved as shown by an overlay
of CDK1 (extracted from the structure of CDK1–Cks2), CDK2, CDK6, CDK7 and CDK16 structures. The other CDK folds are superposed on CDK2: CDK1 (PDB 4YC6, light
grey); CDK6 (PDB 5L2S, cyan); CDK7 (PDB 1UA2, magenta) and CDK16 (PDB 5G6 V, light green). Mobility is indicated by the quality of the experimental electron
density maps, so that the derived structures can be traced with varying degrees of confidence. (c) The various conformations the activation and glycine-rich loops can
adopt are highlighted by this structural comparison. Structures reported for these loops may represent more populous low energy conformations compatible with a
particular crystal lattice. This model is supported by studies of monomeric CDK2 phosphorylated on the conserved threonine residue within the activation loop (T160
in CDK2), which exhibits approximately 0.3% of the fully active CDK2–cyclin A complex ([40], PDB 1QMZ). The majority of the CDK2 probably corresponds to inactive
conformations, but a small fraction is in an active conformation and generates the basal activity observed.
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cyclin binding.
The flexibility of the CDK fold has also been captured in
ATP-competitive inhibitor-bound structures where inhibitor
binding helps to stabilize alternative energetically less favour-
able conformations. At the start of the activation loop, the
conserved DFG motif can adopt either an active ‘DFG-in’ con-
formation (figure 3), or an inactive ‘DFG-out’ conformation in
which the phenylalanine side chain points into the active-site
cleft and is removed from its position in the ‘regulatory spine’
of residues that characterizes the active protein kinase fold
[53]. This latter conformation has been exploited for the
design of several tyrosine kinase-specific inhibitors [54,55].
Though the majority of CDK ATP-competitive inhibitor struc-
tures determined to date have a ‘DFG-in’ conformation [32],
inhibitor binding to monomeric CDK2 ([56], PDB 5A14)
and monomeric CDK16 ([38], PDB 5G6 V) and to cyclin-
bound CDK8 (PDB 3RGF) can stabilize the CDK fold into a‘DFG-out’ conformation. Thus, the binding of ATP-competi-
tive inhibitors interrogated by the determination of multiple
‘snapshots’ of protein kinase structures highlights the
inherent flexibility of the CDK fold and its ability to adopt
multiple conformations [31,55].2.3. Extending the activation model to other cyclin
partners of CDK1 and CDK2
CDK1 is the closest member of the CDK family to CDK2 and
for which structures of the cyclin-free and authentic cyclin-
bound forms can also be compared (figure 3b; [34], PDB
codes 4YC6 and 4YC3). It is the only essential CDK and, acti-
vated by its partners cyclins A and B, it executes progression
through mitosis. Overall, the mechanism of CDK1 activation
is conserved with CDK2. However, an opening of the inter-
face coupled with a twist between the two proteins relative
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Figure 3. CDK activation by cyclin binding. (a) Overlay of monomeric CDK2 and T160-phosphorylated CDK2–cyclin A. Cyclin A composed of two tandem cyclin box
folds (CBFs [49], PDB 1VIN) acts as a scaffold to which the malleable unphosphorylated CDK responds to generate a binary complex that exhibits basal activity ([47],
PDB 1JST). The CDK aC-helix is rotated and relocated into the active site by engagement with the N-CBF of the cyclin subunit. At the start of the activation loop,
aL12 is melted and the conserved DFG motif adopts an active ‘DFG-in’ conformation in which the aspartate side chain coordinates a magnesium ion to productively
orientate the ATP phosphate groups for catalysis. The activation loop is extended and pulled away from the active site to form a platform that will ultimately
recognize the protein substrate around the site of phospho-transfer ([50], PDB 1QMZ). Cyclin binding also refines the relative positions of the CDK2 N- and C-terminal
lobes, so that residues within the hinge and lining the active site orientate the ATP adenine and ribose rings and phosphate groups for catalysis. Overall, the
CDK2–cyclin A interface is extensive (2839 A˚2, [51]) extending between both lobes of the CDK and the two cyclin CBFs, further strengthened by engagement
of the cyclin N-terminal helix preceding the N-CBF with the CDK C-terminal lobe. The phospho-threonine within the activation loop (T160 in CDK2) acts as a
structural hub liganded by conserved, positively charged residues located within the C-helix (R50), at the start of the activation loop (R150) and adjacent to
the catalytic aspartate residue (R126). In the absence of T160 phosphorylation, a conserved C-terminal glutamate residue (E162 in CDK2) satisfies the positively
charged side chains of the phospho-threonine-binding pocket, and the side chain hydroxyl of T160 is solvent accessible within the context of a relatively well-
ordered activation loop ([47], PDB 1JST). The inactive conformation of CDK2 is shown as a translucent ribbon. The N-CBF and C-CBF are also shown.
(b) CDK1–cyclin B (PDB 4YC3; CDK1 grey, cyclin B translucent cyan surface). Inactive (cyclin-unassociated) CDK1 conformation shown as a translucent ribbon.
(c) CDK2–Spy1 is shown in a similar pose (PDB 5UQ2; CDK2 blue, Spy1 translucent pink surface). (d ) Comparison of unphosphorylated CDK2–cyclin A (PDB
1FIN; activation loop, red), T160-phosphorylated CDK2–cyclin A with peptide present (PDB 2CCI; peptide, yellow activation loop, deep red) and CDK2–Spy1
(PDB 5UQ2; activation loop in brown) activation loop conformations. The positions of residues (P23 to Pþ3) within the CDC6 peptide substrate (sequence
HHASPRK) with respect to the serine residue at the site of phospho-transfer (P position) are indicated.
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and fewer interactions between the cyclin B and CDK1
C-terminal lobes. Overall, the interfacial surface is 30%
smaller in CDK1–cyclin B compared with CDK2–cyclin
A. Crystallographic electron density maps of unphosphory-
lated CDK1 suggest that it has a more flexible activation
segment than does the comparable state of CDK2.
A comparative analysis of the sequence loci that mediate
the CDK1– and CDK2–cyclin interfaces reveals the con-
served sequence features that may explain CDK1 and CDK2
cyclin selectivity [34]. CDK2 is partnered by cyclin E during
late G1 phase and then subsequently by cyclin A [1]. Under
circumstances where CDK1 expression is knocked down, itcan also partner cyclin B [57]. A comparison of the structures
of phosphorylated CDK2 bound to cyclin A ([48], PDB 1JST),
cyclin B [58], PDB 2JGZ) and cyclin E ([51], PDB 1W98)
revealed the conserved nature of the CDK2 response to
cyclin binding [34]. Cyclins A and B conserve three large aro-
matic residues at the CDK–cyclin interface (Y170, Y177 and
Y258 in cyclin B), whereas in cyclin E the residues at these
positions have smaller side chains (N112, I119 and L202).
Given the smaller CDK1–cyclin interface compared with
CDK2–cyclin A, the structures would predict that CDK1
would bind preferentially to cyclins B and A, but that these
smaller side chains would have less impact on CDK–cyclin
affinity in the context of the larger CDK2–cyclin interface.
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A/B/E structures also highlights the potential for these
closely related CDKs to be differentially regulated by
reversible phosphorylation. The antagonistic activities of
Wee1/Myt1 kinases and Cdc25 phosphatases regulate the
phosphorylation status of the CDK glycine-rich loop (defined
by the GXGXXG motif, residues 11–16 in CDK2). The struc-
ture of CDK2–cyclin A phosphorylated on Y15 illustrates
how phosphorylation promotes a glycine loop structure
that antagonizes both peptide substrate binding and the
ATP conformation required for catalysis [59]. The flexibility
of the glycine-rich loop is compatible with a model in
which the phosphorylated Y15 side chain is solvent exposed
and accessible to both kinases and phosphatases. CDK1 is
also regulated by active-site phosphorylation, and the con-
served nature of the structure in this region suggests that
the mechanism of inhibition is also conserved.
However, unlike the glycine-rich loop, the flexibilities of
the phosphorylated CDK1 and CDK2 activation loops
differ. Though the structure of a T161-phosphorylated
CDK1–cyclin B complex is yet to be determined, this com-
plex is susceptible to phosphatase treatment, suggesting
that the phosphorylated CDK1 activation segment remains
flexible [34]. By contrast, phosphorylated CDK2 T160 is
embedded within a network of ionic interactions (figure 3)
that orders the CDK2 activation segment within this region
and decreases T160 solvent accessibility. Taking Y15 as the
model, this difference could ensure that the activity of
CDK1, more so than that of CDK2, remains subject to the
ongoing antagonistic activities of CAK and phosphatases.
In particular, it would offer an opportunity for CDK1 to be
subject to rapid enzyme-mediated inactivation even in the
presence of high concentrations of cyclin B and might offer
a regulatory opportunity to distinguish CDK1 and CDK2
activities.
Ringo/Spy proteins also activate CDK1 and CDK2 and
represent a divergent branch of the cyclin family, identified
through their ability to induce meiotic maturation in Xenopus
oocytes [60,61], an activity conserved in humans [62]. Ringo
A/Spy1 is required for localizing CDK2 to telomeres, and
its absence results in defects in chromosome tethering to
the nuclear envelope [63,64]. Several studies have implicated
Spy1 in glioma, suggesting that it may also have functions in
mitosis in selected cell types [65]. Ringo A knockout mice
show similar defects to CDK2 knockout mice during sperma-
togenesis [63], suggesting that the essential function of CDK2
during meiosis might be mediated, in part, by its association
with Ringo A. Spy1 (Ringo A) encodes only a single CBF
embedded within a longer sequence and activates CDK2
through a mechanism that does not require activation loop
phosphorylation (figure 3c; [66], PDB 5UQ2). Immediately
after the DFG motif, CDK2 R157 and T158 anchor the acti-
vation loop through electrostatic interactions with Spy1
D97 and E135, respectively. CDK2 R50 and R150 that
coordinate the phosphorylated CDK2 T160 side chain in the
CDK2–cyclin A structure interact with Spy1 D136, so that
its carboxylate moiety effectively mimics a number of
interactions made by the phosphoT160 phosphate group.
These alternative interface interactions create a CDK2
activation loop conformation most reminiscent of that seen
when it is bound to cyclin A (figure 3d ). The resulting com-
plex has measurable kinase activity but is less active than
phosphorylated CDK2–cyclin A [66].2.4. Comparison of the crystal structures of CDK–cyclin
complexes
To what extent the mechanism for CDK activation proposed
through studies on CDK2 can be extended to other members
of the CDK and cyclin families has been challenged by
further CDK–cyclin structures. Cyclin-free structures are
not available for other CDKs determined in their cognate
cyclin-bound states, so inferences about the mechanism of
activation can only be made by presuming a conserved inac-
tive monomeric CDK fold. Taken together, they provide
diverse examples of how CDK activation can be achieved;
models for activation of CDK5 and CDK4, in particular, are
quite distinct.2.4.1. CDK4 and CDK6
CDK4 and CDK6 are frequently considered together as
promoters of G1 progression. In this context, they phosphor-
ylate relatively few substrates, notably the retinoblastoma
protein, its relatives and a number of transcription factors
[67]. A structure for a CDK6–cyclin D complex has not been
determined, but CDK6 bound by a viral cyclin provides
another illustration of how an alternative CDK–cyclin inter-
face generates an active CDK conformation in the absence of
activation segment phosphorylation (figure 4a; [68], PDB
1JOW). Viral cyclin binding re-organizes the CDK6 C-helix
and ensures that the path of the activation segment C-terminal
to T177 (equivalent to CDK2 T160) forms a peptide-binding
platform equivalent to that seen in CDK2. A novel b-sheet
interaction made between the CDK6 sequence preceding
T177 and the viral cyclin N-terminal sequence, that has no
counterpart in any other known CDK–cyclin complex
structure, stabilizes the activation segment.
The structures of non-phosphorylated and phosphory-
lated CDK4 bound to cyclin D3 ([69], PDB 3G33; figure 4c)
or cyclin D1 ([70], PDB 2W96; figure 4b), respectively, revealed
that the structural mechanism of CDK4 activation must be dis-
tinct from that of CDK1 or CDK2. Only the cyclin D
N-terminal CBF (N-CBF) binds to CDK4, the C-terminal
lobes of both proteins are splayed apart to create a solvent-
filled cleft between the two subunits. Cyclin D binding does
not induce an active CDK4 conformation. In both structures,
the CDK4 C-helix remains displaced, reminiscent of cyclin-
free CDK1 and CDK2, and the activation loop is either largely
disordered (CDK4–cyclin D3) or adopts a conformation that
occludes the active site and is incompatible with substrate
binding (CDK4–cyclin D1). Based on these structural insights,
a substrate-assisted model of CDK4–cyclin D catalysis has
been proposed in which substrate engagement with the
cyclin at the RXL site (see below) promotes the transient
folding of the CDK4 into an active conformation [69].
The CDK4 activation loop remains accessible to cycles of
phosphorylation and dephosphorylation by CAK and
phosphatases, respectively [69]. In cells, sustained CAK
activity is required to maintain CDK4 and CDK6 activity
[71], an observation supported by the CDK4–cyclin D struc-
tures. It can be hypothesized that CDK6 bound to cyclin D1,
D2 or D3, in contrast to the structure it adopts bound to a
viral cyclin (described above), might also retain flexibility
in the activation loop around T177. Whether CDK6–
cyclin D resembles CDK4–cyclin D1/D3 or alternatively
CDK6–viral cyclin CDK4–cyclin D1
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Figure 4. CDK–cyclin complexes. A comparison of the CDK–cyclin complexes, for which structures are available, highlights the differences in the CDK response to
cyclin association. (a) CDK6–viral cyclin (PDB 1JOW, CDK6, cyan with activation loop (residues 163–189) shown in red; viral cyclin, grey). (b) CDK4–cyclin D1 (PDB
2W96, CDK4, orange; cyclin D1, light purple, RXL-binding site shown as a red translucent surface (residues 54–61) and partially resolved LXCXE motif shown in cyan
(residues 6–9)). (c) CDK4–cyclin D3 (PDB 3G33, CDK4, orange; cyclin D3, purple, RXL-binding site shown as a red translucent surface (residues 56–61). (d ) CDK5–
p25 (PDB 1H4 L, CDK5, light blue with activation loop (residues 144–171) shown in red; p25, gold). (e) CDK8–cyclin C (CDK8, green with C-terminal residues
343–353 in orange; cyclin C, purple). ( f ) CDK9–cyclin T1 (PDB 3BLH, CDK9 lilac with C-terminal residues 317–325 in orange; cyclin T, pale yellow). (g) CDK12–
cyclin K (PDB 4UN0, CDK12, light grey, C-terminal rail residues 1025–1036 in orange; cyclin K, green). (h) CDK13–cyclin K (PDB 5EFQ, CDK13, gold, C-terminal tail
residues 1011–1025 in orange; cyclin K, green). The activation segment sequences are shown in red where resolved in the structures.
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context of a cyclin-activated structure (i.e. more reminiscent
of the structure of CDK1–cyclin B) will require the determi-
nation of the structure of CDK6 bound to a cognate cyclin.
The conserved nature of the CDK4/6 active sites and theirability to adopt similar structures is exemplified by the suc-
cessful recent registration for clinical use of highly selective
ATP-competitive CDK4/6 inhibitors [72].
However, there are structural differences between CDK4
and CDK6 that can impact function. For example, whereas
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way, CDK4 is a strong client [73–76] and many of its
partner proteins regulate protein folding and complex assem-
bly [77]. These differences in stability are reflected in the
affinities of CDK4 and CDK6 for various regulatory proteins
[78]. Taken together, these results suggest that CDK4 is an
unstable protein that is prone to unfolding and whose integ-
rity is dependent on protein association, a model further
substantiated by structural studies of a CDK4–Cdc37–
Hsp90 complex [79] (see below).
2.4.2. CDK5
CDK5 is expressed in post-mitotic neuronal cells where it
binds to p35 and p39 and phosphorylates key regulators
such as tau and b-APP [9]. Dysregulation of CDK5 activity
was initially characterized in the context of neurodegenera-
tive diseases and neurological disorders [80], although there
is increasing evidence that, in certain cellular contexts, it
can also contribute to tumorigenesis [81,82]. p35 proteolysis
promoted by neurotoxic conditions generates p25, a C-term-
inal fragment that retains the ability to activate CDK5. p25
encodes eight a-helices that have a related but distinct top-
ology when compared with the cyclin A N-CBF (figure 4d;
[83], PDB 1H4 L). Overall, given their different relative helical
dispositions, it is difficult to make direct comparisons
between the cyclin A and p25-mediated CDK interfaces,
except that they both stabilize an active CDK conformation.
Two loops linking p25 a1 to a2 and a3 to a4 make extensive
contacts with the CDK5 activation segment and stabilize a
non-phosphorylated active conformation. Within this
region, CDK5 has three arginine residues spatially equivalent
to the three arginines that coordinate CDK2 phosphoT160,
and two of them (R50 and R149) are alternatively employed
at the p25 interface.
CDK5 can also bind to cyclin E [84]. The adult brain
expresses high levels of cyclin E, which can compete with
p35 for CDK5 and inhibit CDK5 activity. In its absence,
unrestrained CDK5–p35 activity can lead to pathological
synapse growth, and formation of CDK5–cyclin E complexes
promotes synapse formation. A number of CDKs have mul-
tiple authentic cyclin partners that post-CDK activation can
impose distinct substrate preferences on their CDK partner.
However, this example is distinguished in that cyclin binding
inhibits CDK activity.
2.4.3. Transcriptional CDKs, CDK8, CDK9, CDK12 and CDK13
Within the transcriptional CDKs sub-branch, CDKs 7, 8/19
and 9 are found, respectively, as components of TFIIH, the
mediator complex CDK8 kinase module (or its paralogous
complex containing CDK19) and positive transcription
elongation factor b (P-TEFb). Collectively, they phosphorylate
both specific residues within the heptad repeats that consti-
tute the CTD (CDKs 7 and 9) and associated factors (CDKs
7, 8/19 and 9). CDK7 [85] and CDK8 [86,87] regulate the
initiation of transcription and CDK9 subsequent release
from promoter proximal arrest [88] (reviewed in [89]).
CDK12 [90–92] and CDK13 [93] bound to cyclin K are associ-
ated with transcript synthesis towards the middle and 30-end
of the emerging RNA, at which point they phosphorylate
the CTD-heptad repeats. CDK12–cyclin K also regulates
alternative last exon splicing [94].CDK12–cyclin K promotes pre-replicative complex for-
mation during G1 by regulating the activity of cyclin E1
[95]. CDK12–cyclin K has also been reported to regulate
the expression of a subset of genes that mediate the DNA
damage response [91] and CDK13 gene sets that are involved
in growth signalling [93]. Mutations in CDK13 are associated
with developmental heart defects and intellectual develop-
ment, suggesting it is required for the execution of specific
gene expression programmes [96]. To what extent these
CDKs balance activities as part of the core machinery of
RNA pol II-dependent transcript processing against activity
on subsets of genes is yet to be fully characterized. A charac-
teristic of CDKs 12 and 13 is the presence of much longer
sequences N- and C-termini to the conserved catalytic fold
than is found in other transcriptional CDKs (figure 1).
These sequences are as yet not structurally characterized
but do contain a number of arginine/serine-rich and pro-
line-rich motifs (amongst others) and regulate CTD
phosphorylation [97].
CDK–cyclin structures have been determined for a sub-
stantial subset of the transcriptional branch of the CDK
family, CDK8 bound to cyclin C ([98], PDB 4F7S; figure 4e),
CDK9 bound to cyclin T ([99], PDB 3BLH; figure 4f ) and
CDK12 ([100], PDB 4UN0; figure 4g) and CDK13 ([93], PDB
5EFQ; figure 4h) bound to cyclin K. CDK8, CDK9 and
CDK12 are reminiscent of CDK4 and engage their cyclin part-
ners almost exclusively through their respective CDK and
cyclin N-terminal lobes. However, the CDK8–cyclin C inter-
face is made more substantial by additional interactions
between an N-terminal helix present in CDK8 that recognizes
the cyclin C N-CBF. The CDK12–cyclin K interface is also
more extensive than that between CDK9 and cyclin T,
mediated by further interactions between the CDK12 N-term-
inal lobe and the N-terminal region of cyclin K. Cyclin T
binding and activation loop phosphorylation creates a
CDK9 peptide-binding platform reminiscent of that seen in
CDK2–cyclin A [99]. Interestingly, these three cyclin-bound
CDKs differ in their activation mechanisms: CDK9 can auto-
phosphorylate in cis on T186 in vitro [99], but in vivo
phosphorylation is CDK7-dependent [101], as is phosphoryl-
ation of CDK12 [102]. CDK8 is active in the absence of
activation loop phosphorylation [103].
A more detailed structural comparison highlights other
structural differences that impact activity and regulation. The
first CDK8–cyclin C structure (PDB 3RGF) was crystallised
in the presence of sorafenib which imposed a ‘DMG-out’ con-
formation at the start of the CDK8 activation loop [103].
A substantial fraction of the following activation loop sequence
proved to be flexible and could not be built between resi-
dues R178 and V195, encompassing the predicted peptide
substrate-binding site. Subsequent structures of apo
CDK8–cyclin C (PDB 4F7S, [98]) and other CDK8–cyclin C–
ATP-competitive inhibitor structures in a ‘DMG-in’ confor-
mation ([98,104], PDB 4CRL; [105], PDB 5CEI) were also
disordered in this activation loop region. Notably, the CDK8-
specific loop linking helices aF and aG (residues 239–247),
which lies below the activation loop, is also disordered. These
observations suggest that association with other components
of the Mediator complex may be required to stabilize the
CDK8 structure in this region to activate its activity.
Taken together, the transcriptional CDKs are all character-
ized by having an extended, flexible C-terminal tail beyond
the kinase catalytic core fold (figure 4e–h). Where structures
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Figure 5. Shaping of the catalytic cleft by the C-terminal tail in the transcriptional CDKs. In each case, the binding of an ATP-competitive inhibitor (ball and stick
model) within the ATP-binding pocket helps to order the C-terminal sequence. (a) CDK8–cyclin C–CCT251545 (PDB entry 5BNJ); (b) CDK9–cyclin T1–DRB (PDB
3MY1) overlaid with the full-length CKD9 structure (PDB 4RC8); (c) CDK12–cyclin K–THZ531 (PDB 5ACB). In this structure, the inhibitor THZ531 forms an irreversible
bond with C1039 located within the CDK12 C-terminal extension. The CDK8, 9 and 12 folds are coloured green, lilac and grey, respectively, and the CDK C-terminal
tails are coloured orange. The hinge region between the N- and C-terminal kinase lobes and the aC-helix is identified to provide the context.
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the character of the ATP-binding site (figure 5). The CDK9 C-
terminal tail is anchored by conserved residues F336 and
E337 that bind, respectively, into a hydrophobic pocket just
before the hinge sequence and into the ATP-binding site
([106], PDB 4EC8). A model can be proposed that, during
the catalytic cycle, the active, closed-state conformation is
stabilized by folding of the C-terminal tail, generating a
fully enclosed active site bounded on one side by the C-term-
inal tail and on the other by the peptide substrate. Notably,
CDK9 follows an ordered reaction mechanism in which
ATP binds first and ADP is released last [106]. Mutation of
F336 and E337 to alanine or deletion of the C-terminal tail
converts the mechanism to a random one (cf. CDK2 or
CDK5, [107]), suggesting that conformational cycling of the
tail sequence imposes reaction order. This kinetic analysis
supports a distributive rather than processive mechanism
for CTD phosphorylation by P-TEFb (see also [108]), which
might impact the distribution of phosphorylation events on
the CTD sequence [109,110]. Substrate (ATP) trapping in a
closed state is a feature of a CDK12–cyclin K-AMP–PNP
complex (PDBs 4NST [102]; and 4CXA [100]) and of a
CDK13–cyclin K–ATP complex where residues within the
tail make direct interactions with ATP ([93], PDB 5EFQ).
The binding of various ATP-competitive inhibitors also
orders the CDK8 C-terminal tail (figure 5a) ([104], PDB
4CRL; [105], PDB 5CEI; [111], PDB 5IDN; [112], PDB 5BNJ;
and [113], PDB 5HVY). Beyond its ability to shape the ATP-
binding site, it remains to be determined to what extent the
conformational flexibility of the C-terminal tail is employedas a structural mechanism to regulate this sub-branch of the
CDK family.3. CDK substrate recognition
The structure of CDK2–cyclin A bound to a non-hydrolysa-
ble ATP analogue and an optimal substrate peptide
(HHASPRK) revealed how the activation segment is mod-
elled to recognize a proline residue at the P þ 1 position
and a positively charged residue at P þ 3 (where P is the
phosphate-accepting residue) ([50], PDB 2CCI; figure 3d ).
Structural studies support a dissociative mechanism through
a metaphosphate intermediate in which the attacking group
(serine or threonine hydroxyl) from the peptide substrate
comes in opposite to the leaving group (phosphate ester
oxygen of the g-phosphate group of ATP), leading to inver-
sion of configuration at the phosphorus (PDB codes: 3QHR
and 3QHW [114], and 1GY3 [115]). Apart from this motif,
the only other significant sequence feature shared by many
cell cycle CDK substrates is the RXL motif, first identi-
fied by comparative sequence analysis of multiple CDK
substrates and inhibitors [116]. This sequence binds to a site
on the cyclin N-CBF that is conserved between cyclins A, B,
D and E, and was first structurally characterized following
the determination of the structure of a CDK2–cyclin
A–p27KIP1 complex (PDB 1JSU, [117]).
A feature of the cyclin B-bound CDK1 is the retention of
flexibility within the activation loop upon T161 phosphoryl-
ation [34] (figure 3b). Using a series of model peptide
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CDK1, this enhanced flexibility translates into a more relaxed
substrate preference around the site of phospho-transfer [34].
In the presence of an RXL motif, CDK1 will phosphorylate
motifs that contain either a proline residue at P þ 2 or a posi-
tively charged residue at P þ 3. CDK1 is characterized by its
promiscuous ability to phosphorylate a wide variety of sub-
strates at multiple sites, many of which are ‘non-canonical’
[116,118–120]. The structure of CDK1 suggests a mechanism
by which activation loop flexibility, embedded in an
inherently, more flexible CDK1 fold allows CDK1 to accom-
modate a more diverse substrate set than its nearest relative
CDK2. These plastic properties may also contribute to its abil-
ity to partner non-cognate cyclins in the absence of other
CDKs to drive the cell cycle [34,121].
The structures of CDK4 bound to cyclin D1 and cyclin D3
support a model in which a catalytically competent active-site
configuration must occur transiently when CDK4–cyclin D
forms a Michaelis complex with ATP and protein substrates
(figure 4b,c). Purified CDK4–cyclin D3 requires the presence
of an RXL motif within the peptide substrate for activity,
suggesting that substrate engagement through the cyclin
recruitment site promotes both productive substrate engage-
ment and kinase remodelling. Such a substrate-assisted
catalysis model would be supported by kinetic studies in
which CDK4 has been shown to follow an ordered sequential
mechanism in which ATP binds first and the phospho-pep-
tide product leaves last [122]. CDK4/6–cyclin D complexes
monophosphorylate pRB at multiple sites and further hyper-
phosphorylation is mediated by CDK2–cyclin E [123].
Although it is not clear what function monophosphorylation
performs, taken together, these observations suggest that
CDK4 activity is more tightly regulated by substrate scaffold-
ing than CDK1 and CDK2. Whether the model extends to
CDK6 awaits the determination of the structure of CDK6
bound to an authentic D-type cyclin.
The RXL-binding cyclin recruitment site was the first to
highlight the use of substrate docking sites to enhance CDK
activity towards particular substrates [124–126]. Permu-
tations on this sequence can be accommodated with
differing affinities by cyclins to refine substrate recognition
[58,127,128]. Compatible with a docking model, crystallo-
graphic attempts to determine a substrate path between the
RXL and SPXK motifs for the binding of a model substrate
to CDK2–cyclin A failed to resolve electron density for
residues beyond the consensus sequences [129].
The ability of Cks1 to enhance the phosphorylation of a
subset of CDK1 substrates was first recognized in Xenopus
oocytes [130] and refined by further studies in Saccharomyces
cerevisiae [131]. Cks1 binds to the CDK1 C-terminal lobe
(figure 6c) and contains a phospho-threonine docking site
that can recognize phosphorylated CDK1 substrates and
promote their further hyperphosphorylation by CDK1
[132]. The order and pattern of target residue phosphoryl-
ation in multi-site phosphorylated substrates appears to be
fine-tuned by the identity of the cyclin and the presence of
Cks1 [131,133,134].
CDKs 7, 9, 12 and 13 phosphorylate the RNA polymerase
CTD. The sequence of the CTD is unusual, being composed
of 52 heptad repeats in humans, with the consensus sequence
Y-S-P-T-S-P-S. Extracted from cells, CTD residues S2 and S5
are the most abundantly phosphorylated serine residues,
while S7 is phosphorylated to a lesser extent [109,110]. Theextent of phosphorylation within cells was found to be
much less than expected, suggesting that multiple phos-
phorylation events within a single repeat or singly within
adjacent repeats must be infrequent. Various studies have,
together, suggested that the transcriptional CDKs have pre-
ferences for particular sites. For example, CDK7 has been
shown to predominantly phosphorylate S5 and S7, CDK9
to have activity towards all three serines, and CDK12 and
CDK13 to predominantly phosphorylate S2 [135]. Function-
ally significant interplay between phosphorylation sites has
been shown for CDK9 where, using model three hepta-
repeat substrates, S7 phosphorylation was found to prime
subsequent CDK9-mediated phosphorylation. In this study,
pre-phosphorylation of S2 or S5 blocked subsequent CDK9
activity and CDK9 preferentially phosphorylated S5 [108].
Unfortunately, there was no electron density to support bind-
ing of an S2 phosphorylated 13-mer substrate peptide
following attempts to co-crystallize it with CDK13 [93]. To
date, there is no detailed structural information to under-
stand the molecular determinants that distinguish the
activities of the CTD kinases towards their shared substrate
and to what extent the complex local molecular environment
impacts substrate selection.
Other CDK substrate docking sites have been identified
but as yet structural information is lacking. Analysis of a
set of S. cerevisiae Cln2 mutants has identified a surface
shared with Ccn1 and Cln1 cyclin subtypes but not with
Cln3 that recognizes a consensus substrate ‘LP motif’ that is
enriched in leucine and proline residues [136]. Modelling
the Cln2 structure on cyclin A reveals the docking site to be
adjacent but non-overlapping with the RXL-binding site on
the surface of the N-CBF. It is likely that ordered progression
through the cell cycle results both from different CDK–cyclin
pairings having different substrate selectivity and from the
fact that the different CDK–cyclin pairings are expressed at
different points in the cell cycle [137] (reviewed in [138]).4. Regulatory protein interactions
4.1. Cell cycle CDK–cyclins: regulatory interactions
determining activity
A number of cyclin-encoded protein-binding sites or short
peptide motifs have been structurally characterized. A well-
characterized example is the recycling of the cyclin RXL
recruitment site that is exploited to either enhance or inhibit
CDK activity. Alternatively, short motifs encoded within
the cyclin sequence can be used both to dock cyclins to sub-
strates to enhance CDK activity and alternatively to localize
them to CDK regulators frequently resulting in a loss of
CDK activity.
Members of the p27KIP1/p21CIP1 cyclin-dependent
kinase inhibitor (CKI) family share an RXL motif with
RXL-containing substrates and compete with them for
CDK–cyclin association. The structure of a CDK2–cyclin
A–p27KIP1 complex (PDB 1JSU, [117]) revealed the extended
path of the N-terminal sequence of the intrinsically disor-
dered p27KIP1 protein over the upper surface of the cyclin
N-CBF (figure 6a). p27KIP1 then proceeds to disengage the
edge b2-strand from the CDK2 N-terminal lobe and occupy
the ATP-binding site, mimicking the interactions made by
the adenine ring of ATP. p27KIP1 also acts as an assembly
(a) (b)
(d)(c)
(e) ( f )
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Figure 6. CDK–cyclin interaction partners. A number of CDK–cyclin partners and interaction sites have also been solved structurally. (a) CDK2–cyclin A p27KIP1
(PDB 1JST, CDK2–cyclin A, coloured as previous, p27KIP1 is coloured green and the hydrophobic patch of the RXL site is highlighted in orange with p27KIP1 side
chains R30, N31, L32, F33 highlighted). (b) CDK6–p19INK4d (PDB 1BLX, CDK6, cyan; p19INK4D, orange). (c) CDK1–Cks1 (PDB 4YC6, CDK1, grey; CKS1, blue with
phospho-threonine (pT)-interacting residues shown in purple; the peptide from 2CCI (yellow) has been superposed onto 4YC6). (d ) CDK2-KAP (PDB 1FQ1, CDK2, blue
with red activation loop; KAP, green). (e) cyclin E–Fbw7 (PDB 2OVQ, Fbw7, orange; cyclin E peptide, green). (f ) cyclin D1–FBXO31 (PDB 5VZU, FBX031, crimson;
cyclin D1 peptide, pink).
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cyclin D complexes, a role that also sequesters p21CIP1/
p27KIP1 CKIs to promote G1 progression [27,139]. The reten-
tion of CDK activity in the presence of bound p27KIP1 is
linked to the phosphorylation status of p27KIP1 Y88. Phos-
phorylation by tyrosine kinases (e.g. Src or Abl kinases) can
generate CDK4/6–cyclin D–p27KIP1 [140–142] or CDK2–
cyclin A–p27KIP1 [143] complexes that are catalytically
active. The differences in kinetics and affinity of p27KIP1
and p21CIP1 binding to CDK2–cyclin A and to CDK4–
cyclin D complexes may reflect an option for an alternative
binding mode to CDK4 [144–146]. Exploiting NMRmethods,
p27KIP1 Y88 phosphorylation promotes the removal of the
310 helix that occludes the CDK2 active site [143]. The struc-
tural basis of how phosphorylated p27KIP1 binds to
CDK4/6–cyclin D to aid assembly of an active complex is
yet to be elucidated by a co-complex structure.The INK (inhibitors of CDK) family of CKIs selectively
inhibits CDK4 or CDK6 and, through an allosteric mechan-
ism, disfavours CDK–cyclin binding [15]. Their tandem
ankyrin repeat structures exemplified by CDK6–p19INK4d
([147], PDB 1BLX; [148], PDB 1BI8) and CDK6–p16INK4a
([148], PDB 1BI7) bind in the vicinity of the CDK hinge on
the interface opposite to the surface remodelled upon cyclin
association (figure 6b). INK4 binding to CDK6 distorts the
N-terminal kinase lobe relative to the C-lobe by approxi-
mately 158, thus misaligning the key catalytic residues. The
structures of individual INKs have also been determined by
X-ray crystallography (p18INK4c, [149], PDB 1IHB) and
(p19INK4d, [150], PDB 1BD8) or solution NMR (p15INK4b,
[151], PDB 1D9S), (p16INK4a, [151], PDB 1DC2; p18INK4c,
[152], PDB 1BU9; and p19INK4d, [153], PDB 1AP7).
The cell cycle CDKs are further distinguished by the CDK
surfaces they exploit to regulate activity. For example, no
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the CDK1/2 hinge. Similarly, there is no known protein
that binds to CDK4 and CDK6 in a manner equivalent to
the binding of Cks1 or Cks2 to CDK1 ([34], PDB 4YC6;
figure 6c) or CDK2 ([154], PDB 1BUH). The CDK2 C-terminal
lobe also recognizes kinase-associated phosphatase (KAP)
that can dephosphorylate T160-phosphorylated CDK2
([155], PDB 1FQ1; figure 6d ).
In addition to helping to select mitotic substrate phos-
phorylation sites (see above), Cks1 collaborates with Skp2
to form the p27KIP1 phosphoT187-binding site within the
SCFSkp2 (Skp1–cullin–F-box) E3 ubiquitin ligase complex
([156], PDB 2AST). This example is the first to show an
F-box protein requirement for an accessory protein for
substrate recognition [157,158]. Modelling studies using
structures of sub-complexes show that a CDK2–cyclin
A–p27KIP1–Cks1–Skp1–Skp2 complex can be built [156],
but whether any subtle rearrangements occur will require
determination of the structure of the CDK2–cyclin
A–pT187p27KIP1–SCFSkp2 complex.
The LXCXE motif located towards the N-terminus of the
D-type cyclins is highly conserved and represents an interest-
ing example of a short cyclin-encoded motif that assists in
substrate recruitment. D-type cyclins share this sequence
with other cellular and viral proteins that bind to pRB
[159]. In the CDK4–cyclin D1 structure, the motif is seques-
tered in the channel between the C-terminal CDK and
cyclin lobes (figure 4b). However, the quality of the electron
density map shows that it is flexible, suggesting it could dis-
engage and remodel to bind to pRB. The structure of a
complex of the pRB pocket domain and an LXCXE-contain-
ing peptide derived from the human papilloma virus E7
protein illustrates the interaction ([160], PDB code 1GUX). It
is not known whether pRB and cyclin D engagement of
LXCXE and RXL motifs, respectively, is synergistic or antag-
onistic for promoting pRB phosphorylation by CDK4 or
CDK6, but it may be hypothesized to contribute to the mech-
anism that restricts CDK4/6 activity. Mutation of the LXCXE
motif disrupts cyclin D1 activity in some cell line contexts
where cyclin D expression has been reduced [161], but its
mutation in a cyclin D1 ‘knock-in’ mouse study did not
reveal any significant differences to the authentic cyclin D1
sequence [162].
4.2. Cyclin motifs regulating stability
Cyclin levels are tightly controlled and their degradation
is a response to signalling pathway activation. Various E3
ubiquitin ligase complexes target cyclins for degradation,
collectively employing short, flexible degron motifs to recog-
nize their various cyclin substrates. The relationship
between cyclin A- and B-containing CDK complexes and
the anaphase-promoting complex/cyclosome (APC/C) illus-
trates this point [163]. Cyclins A and B are substrates of this
E3 ubiquitin ligase and contain destruction (D) box (consen-
sus motif RxxLx[D/E][Ø]xN[N/S], [164,165]) and KEN box
(consensus motif [DNE]KENxxP) degron motifs [166], and
in the cyclin A sequence, an ABBA motif (consensus motif
KxxFxxYxDxxE, in cyclin A1 residues 132–143) mediates
binding to the APC/C. The ABBA motif is also present in
other proteins that bind to Cdc20 and Cdh1, both activators
of the APC/C [167]. It has also been called a Phe box and
was originally described in BubR1 [167–170].Structural studies exploiting the fact that many APC/C
inhibitors contain pseudo-substrate sequences that bind
more tightly to the APC/C and its regulators than do its sub-
strates have provided opportunities to visualize D-box, KEN
box and ABBA motif binding to the APC/C. How D- and
KEN-boxes bind to the Cdc20 b-propeller domain was
revealed by the structure of the Schizosaccharomyces pombe
mitotic checkpoint complex, the motifs being encoded in
the BubR1/Mad3 subunit [171]. However, optimal D-box
recognition requires an interface generated by an APC/C
co-activator (Cdh1 or Cdc20) WD40 b-propeller domain
and the APC/C subunit Apc10 [172]. The structure of a
BubR1 KEN box-derived peptide bound to Cdc20 confirmed
the nature of the KEN box–Cdc20 interface [173]. A complex
of a peptide containing the ABBA motif (in this case derived
from the S. cerevisiae APC/C inhibitor Acm1) provided a
structural model for this cyclin A sequence, in this case bind-
ing to the alternative APC/C activator Cdh1 [174]. Blades 2
and 3 of the Cdh1 WD40 domain create a channel in which
the peptide sits. As Acm1 also encodes a pseudo-substrate
inhibitory KEN box motif, it also provided models for
cyclin A and B engagement with Cdh1 through these
sequences. The structure of the APC/C and its interactions
with various of its regulators and substrates has been
reviewed recently [175].
Members of an alternative family of E3 ubiquitin ligases,
the Skp1–Cullin–F-box (SCF) complexes also recognize and
degrade cyclins. Structures of cyclin E and cyclin D1 peptides
bound to the F-box proteins Fbw7 and FBX031, respectively,
reveal the diverse mechanisms employed. The cyclin E phos-
pho-degron is encoded within the C-terminal tail (C-terminus
at A410). Cyclin E is phosphorylated by glycogen synthase
kinase 3 (GSK3) at T395 and undergoes autophosphorylation
bound to CDK2 (at S399) to generate the phospho-degron
motif recognized by Fbw7 [176,177]. A C-terminal 31 residue
cyclin E phospho-peptide adopts an extended conformation
straddling across the top of the WD40 propeller (figure 6e).
Phosphorylated S399 and T395 are embedded in networks
of hydrogen bonds, the phosphorylated S399 (S384 in
paper) being more solvent accessible, whereas T395 (T380)
is more buried within a shallow pocket.
Cyclin D1 phosphorylation at T286 by (inter alia) GSK3b
[178] signals its degradation by promoting its nuclear extru-
sion (reviewed in [179]). However, cyclin D1 degradation is
phosphorylation-independent when promoted through this
genotoxic stress-induced pathway. Subsequent recognition
of cyclin D1 by the E3 ubiquitin ligase SCF FBXO31 is not
through direct binding of a phospho-T286-containing amino
acid motif to FBXO31. Instead, the structure of the Skp1–
FBXO31–cyclin D1 phospho-peptide (residues 279–295)
complex revealed that essentially all the interactions between
cyclin D1 and FBXO31 are made by the last four C-terminal
cyclin D1 amino acids (292–295) and not the sequence
immediately around T286 (figure 6f ) [180].4.3. Transcriptional CDKs: regulatory interactions
exploiting alternative protein interaction sites
A comparison of the CDK–cyclin complexes regulating tran-
scription illustrates ways in which the CDK–cyclin unit can
be redeployed to expand the potential options for regulation
by protein–protein interactions. The structural variety shown
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Figure 7. The RXL substrate recruitment site is unavailable in transcriptional cyclins. Differences between the cell cycle and transcriptional cyclin families within the
N-terminal cyclin box fold (N-CBF) reveal different availabilities of the RXL site. (a) The cyclin A RXL site with CDC6 (yellow, PDB 2CCI) and RB-associated protein
( pink, PDB 1H25) peptides bound is unavailable in transcriptional cyclins (b) cyclin T (PDB 3BLH, orange), (c) cyclin K (PDB 4UN0, green) and (d ) cyclin H (PDB
1KXU, blue) due to extended a4 helices and protruding a4–a5 loops.
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exploit multiple alternative interaction mechanisms. The
determination of the monomeric cyclin T2 and CDK9–
cyclin T1 structures revealed that the N-CBF recruitment
site that is highly conserved in the cell cycle cyclins (A, B,
D and E, figure 7a) is not present in cyclin T (figure 7b).
The extra turn at the C-terminal end of cyclin T helix a4
folds over the surface of the N-CBF to occlude L43, the resi-
due structurally equivalent to cyclin A W217, which forms
the heart of the RXL-binding recruitment site. The loop link-
ing helix a4 to a5 composed of residues H112–D123 is also
extended when compared to the similar inter-helix sequence
in cyclin A (T282–T287).
The absence of an N-CBF recruitment site is also a feature
of the other cyclins that partner the transcriptional CDKs.
Cyclin K shares extended a4 and a4–a5 loop structures
with cyclin T, though the paths of the a4–a5 loops diverge
([181], PDB 2I53). But structurally, the effect is the same,
and cyclin K F56 equivalent to cyclin A W217 is occluded
from solvent (figure 7c). In the cyclin H structure ([182],
PDB 1JKW and [183], PDB 1KXU), a shorter a4 helix and
loop linking a4–a5 coupled with displacement of the
N-terminal end of a5 relative to its position in cyclin T exten-
sively remodel the cyclin H structure around R63, the residue
equivalent to cyclin A W217 (figure 7d ). However, the most
significant difference imposed on the surface of the cyclin
H N-CBF in this region is from the C-terminal helix that
extends up from the C-terminal CBF (C-CBF) to makeinteractions with the loop linking the N-terminal helix and
a1 of the N-CBF.
Taken together, these structural changes suggest that this
set of cyclins must exploit alternative surfaces within their
CBFs to mediate protein–protein interactions. That this is
the case was first observed following the determination of
the structure of CDK9–cyclin T in complex with HIV Tat.
Tat promotes HIV transcription by competing with com-
ponents of the inhibitory 7SK snRNP for P-TEFb association
[184,185]. It recruits P-TEFb to the trans-activation response
(TAR) element located at the 50-end of the emerging HIV tran-
script, so that P-TEFb can phosphorylate and release the RNA
Pol II for transcript synthesis [186–188].
Tat adopts an extended conformation and its structure is
dictated by the multiple interactions it makes with P-TEFb
generating a large buried surface area. It exploits the fact
that CDK9 and cyclin T only interact through their respective
N-terminal lobes to occupy the cleft they create between their
C-terminal lobes and, in so doing, stabilizes the CDK9–cyclin
T structure ([189], PDB 3MI9). The Tat acidic/proline-rich
region binds within a depression between the two CBFs
and then forms an extended open hairpin structure to head
across to interact with the CDK9 activation loop. The
cysteine-rich sequence and core are more compact and also
bind into a groove between the CBFs. Two zinc ions are coor-
dinated through multiple cysteine residues within the Tat
sequence, the second zinc site completed by cyclin T1 C261
(figure 8a).
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Figure 8. CDK9–cyclin T binds Tat and AFF4. (a) The HIV Tat protein binds to the C-terminal cyclin box fold (C-CBF) of cyclin T (PDB 3MI9, CDK9–cyclin T-coloured
as previous; Tat, blue). Tat contains an acidic-/proline-rich region and a cysteine-rich region for the coordination of Zn, with the second site completed by cyclin T
C261. (b) CDK9–cyclin T-Tat also binds AFF4 at the C-CBF (PDB 4OGR, AFF4, red).
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ing authentic cyclin T interactions was appreciated with the
determination of the structures of (i) CDK9–cyclin T–AF4/
FMR2 Family member 4 (AFF4) ([190], PDB 4IMY), a scaf-
folding component of the super elongation complex (SEC)
[191], (ii) CDK9–cyclin T–AFF4–Tat ([192], PDB 4OR5 and
[190], PDB 4IMY) and ([193], PDB 4OGR) (figure 8b), and
(iii) CDK9–cyclin T–AFF4–Tat–RNA (PDB 5L1Z). Tat
binds to members of the SEC to rescue stalled RNA polymer-
ase II during the transcription of the TAR element, and thus
reinitiates the viral transcriptional regime [192]. AFF4 binds
to cyclin T1 on the C-CBF, situated on the opposite side of
cyclin T1 to the CDK9 interaction interface [190,192], although
an individual AFF4 helix has been resolved behind the aD
helix in the C-terminal lobe of CDK9 in several, but not all
crystallographic copies.
AFF4 is an intrinsically disordered scaffolding protein that
encodes short dispersed sequences that folds upon binding to
dock to protein partners sequestering them together. The
cyclin T-binding site is within the N-terminal 73 residues of
AFF4 (figure 8b). From L34–E45, the AFF4 sequence extends
along the lower edge of the cyclin T C-CBF, then folds to form
a short helix that docks to make interactions along one helical
face with cyclin T helix a50 (C-CBF) and the C-terminal end of
helix a30 (C-CBF). Beyond L56, AFF4 nudges into the groove
between the CBFs to contact Tat, the region being further
shaped by a modification to the path taken by the cyclin TC-terminal sequence from that adopted in P-TEFb to accom-
modate the two proteins. Taken together, the interactions
help to explain the observed enhanced affinity of Tat for
P-TEFb bound to AFF4 than P-TEFb alone.
The binding of these two P-TEFb regulators to distinct but
adjacent sites within the cyclin T C-CBF provides an opportu-
nity for the integration of information from multiple
signalling pathways that affect P-TEFb activity. Though struc-
tural details are lacking, it is known that the binding of
hexamethylene bisacetamide (HMBA)-inducible protein 1
(HEXIM1), a component of the inhibitory 7SK snRNP particle
[194], interferes with Tat binding ([195–197]), suggesting that
its interaction is also mediated through the cyclin T C-CBF.
The bromodomain protein 4 (Brd4) C-terminal P-TEFb-inter-
acting domain (PID) has been reported to not only interact
with cyclin T [198], but also both Brd4 [197] and HEXIM1
[199,200] have been proposed to also bind to CDK9,
suggesting that the canyon between the two P-TEFb subunits
might also be a hotspot for protein interaction.
4.4. Non-canonical cell cycle CDK–cyclin functions
4.4.1. CDK4/6–cyclin D
In addition to their well-established cell cycle roles, CDK4,
CDK6 and cyclin D also regulate many other aspects of cell
behaviour such as transcription, cell metabolism [201–203],
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[28,29,206,207]). Some of these functions are reported to
require CDK4 or CDK6 kinase activity, but others apparently
do not, suggesting that CDK4, CDK6 and cyclin D may, in
certain contexts, act independently and scaffold or maintain
the integrity of larger signalling complexes. Whether CDK4
and CDK6 can be cyclin D-associated but not have kinase
activity remains to be determined [208,209]. By analogy
with receptor tyrosine kinases, where downstream signalling
is elicited by limited activity against a small set of spatially
optimized substrates, it can be hypothesized that CDK4
and/or CDK6 roles in regulating transcription might result
in some cases from their incorporation into large, chroma-
tin-bound complexes at gene promoters where their
substrates are co-located. The importance of these emerging
CDK4/6 and cyclin D functions to disease is being revealed
by proteomic analyses to characterize differences in CDK4/
6 and cyclin D interactomes between normal and oncogenic
states with the aim to identify changes promoting cell
transformation (for example, see [77]).
Cyclin D isoform-specific functions distinguish the pheno-
types of the cyclin D knockout mice [210] and are clearly
important clinically (for example, see [211]). In some cases,
these functions appear to be kinase independent. For example,
D-type cyclins have been reported to act in a kinase-indepen-
dent manner to antagonize the activity of the transcription
factor DMP1 [212]. Subsequent studies have shown that
D-type cyclins can enhance the transcriptional activity of,
for example, the oestrogen receptor [213–215], but inhibit
the activity of another hormone receptor, namely the andro-
gen receptor [216–218]. Cyclin D can also engage with
general transcription regulators and chromatin-modifying fac-
tors such as the histone acetyltransferase p300 [219] and can
affect chromosome integrity [220]. The importance of cyclin
D1 to the regulation of transcription has been highlighted in
a recent proteomic study that identified cyclin D1-binding
transcription factors in different organs during both normal
mouse development and in tumorigenesis [221]. Cyclin D1
is also an important component of the cell’s response to
DNA damage, promoting repair [222–224]. Bound to chroma-
tin, it can recruit RAD51 and localize to sites of DNA double-
strand breaks through a BRCA2-dependent mechanism [225].
Tissue-specific roles of the D-type cyclins are also evident
outside of cancer in the central nervous system [226–228],
where cyclin D2, but not D1 or D3 knockout mice, are
incapable of adult brain neurogenesis [226], suggesting a
cell-cycle-independent role. Mutations to cyclin D2 T280
(equivalent to cyclin D1 T286) that prevent its phosphoryl-
ation by GSK3b and subsequent nuclear export leading to
proteasomal degradation result in elevated cyclin D2 levels
that cause megalencephaly–polymicrogyria–polydactyly–
hydrocephalus syndrome (MPPH, a developmental brain
disorder) [229]. Individuals with elevated cyclin D2 as a
result of cyclin D2mutation rather than activatingmutations in
the PI3 K–AKT–GSK3b pathway have an increased incidence
of polydactyly, suggesting that characteristics of the cyclin D2
overexpression phenotype might also result from a potential
role in regulating a programme of gene expression as well as
promoting the aberrant expansion of neural precursors.
A comparison of the structures of cyclin D1 and cyclin D3
illustrates the extent of sequence conservation between the
three isoforms and reveals the locations of conserved iso-
form-specific surfaces (figure 9). Many of the transcriptionfactors that bind to cyclin D do not encode an obvious RXL
motif, suggesting that they may employ an alternative binding
site on the cyclin D surface. It can also be hypothesized that
some of these interactions may be indirect, for example
bridged through binding of cyclin D to RXL-containing tran-
scriptional regulators such as members of the E2F family.
Many activities of cyclin D in transcription are reported to be
kinase-independent, which suggests that the cyclin D CDK4/
6 interface may be accessible, although a kinase activity-
independent scaffolding role of a CDK–cyclin D complex
cannot be excluded. Given the structural similarities between
the relative dispositions of the CDK and cyclin subunits in
CDK4–cyclinD1/D3andCDK9–cyclinT (figure 10), it remains
a possibility that a protein interaction site on the cyclin
C-terminal lobe is conserved between cyclin T and cyclin D.
4.4.2. Cyclins E and A
Both cyclin A and cyclin E have also been reported to have
CDK-independent roles suggesting scaffolding or regulatory
functions. However, structural details as to whether these
protein interactions require the RXL-binding site on the
N-CBF overlap with other parts of the p27KIP1-interacting
surface or employ novel binding sites are not known. Simi-
larly, there are structurally unverified reports of cell cycle
regulators binding to RNA. As examples, CDK2 and
p21CIP1 have been reported to bind to Foxo3 circular RNA
[230] and cyclin A2 to the 30-untranslated region (UTR) of
Mre11 mRNA [231]. This latter interaction is independent
of an associated CDK partner and regulates Mre11 trans-
lation. Mutational analysis mapped the binding site to the
C-CBF at a surface not previously implicated in protein
association, suggesting that the surface of cyclin A may be
more widely exploited than previously thought.
A number of studies have highlighted potential kinase-
independent functions of cyclin E [232–234]. Cyclin E1 and
E2 knockout mice are, respectively, viable or infertile in
males, and double knockouts are embryonic lethal
[232,235]. These phenotypes demonstrate the necessity for
at least one E-type cyclin in the embryo. Mutations to alanine
within the CDK2-binding interface of cyclin E, in a loop
region between helices H3 and H4, permit weak, p21Cip1/
p27Kip1-dependent binding to CDK2, but abolish cellular
kinase activity. These kinase-activity-deficient mutants re-
established the observed transformative potential of cyclin
E and restored MCM protein loading onto the pre-replication
complex to facilitate G0–S-phase transition [232]. Cyclin E
also localizes to centrosomes independently of CDK2 [236],
which may be relevant to centrosome duplication [237]. In
terms of cancer transformative potential, analysis in rat
embryonic fibroblasts has also suggested that this property
of cyclin E may, in certain circumstances, be independent of
CDK2 [234], an observation that is also consistent with ana-
lyses conducted in hepatocellular carcinoma (HCC) [233].
Cyclin E12/2/E22/2 mice stopped tumour cell proliferation
in clonogenic assays [233], while the individual function of
cyclin E subtypes was resolved in hepatocyte-specific NEMO
and global CCNE1 or CCNE2 knockout mice [238]. Cyclin
E1, and not cyclin E2, was shown to be coupled with liver
disease and hepatocarcinogenesis in this model system [238].
The kinase-independent nature of cyclin E inHCCprogression
was also highlighted by the finding that CRISPR/Cas9 CDK2
deletion and kinase dead forms of CDK2were not sufficient to
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Figure 9. Cyclin D sequence conservation. (a) Sequence conservation between the cyclin D isoforms has been mapped onto the structure of CDK4–cyclin D1 (PDB
2W96) and is represented by blue-scale colouring. (b) Alignment of cyclin D1/2/3 conducted in CLUSTAL OMEGA and output into EXPASY BOXSHADE. Secondary structure
elements for cyclin D1 are shown above the sequence. CDK4 is coloured orange. The UniProt codes used for sequence alignment are: cyclin D1 (P24385), cyclin D2
(P30279) and cyclin D3 (P30281).
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evidence fromcyclin E amplified high-grade serous ovarian car-
cinoma, which suggest that these particular subtypes are
sensitive to CDK2 knockdown through RNA interference
[239,240]. Taken together, these results suggest that cyclin E
has kinase-independent roles and that there are subtle differ-
ences by which cyclin E and its CDK–partner CDK2 are
exploited in cancer progression. Again, whether uncharac-
terized CDK2– and cyclin A or E–protein interaction sites
mediate these activities awaits further study.5. Aberrant mutations/processing—
structures relate to dysregulated
function
CDK–cyclin-containing protein complexes have been impli-
cated in a range of disease settings [8,241,242]. In cancer, in
particular, therapeutic design and development has been
directed at targeting members and regulators of the cell
cycle CDK–cyclin families [25,30,72,243], with emphasis on
(a)
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90°
90°
90°
CDK2 cyclin A
CDK4 cyclin D1
CDK9 cyclin T
 
cyclin A C-terminal tail   
Tat AFF4
AFF4
Tat
a5¢
a4¢
a3¢
a2¢
a1¢
N-CBF
C-CBF
C-CBF
N-CBF N-CBF
C-CBF
N-CBF
C-CBF
N-CBF
C-CBF
a5¢
a3¢/H3¢
a5¢/H5¢
a3¢
Figure 10. Comparison of cyclin T, cyclin D and cyclin A structures in the vicinity of the AFF4-binding site. (a) CDK2–cyclin A showing the C-CBF with the
C-terminal cyclin A tail (orange) accommodated (PDB 1FIN, CDK2–cyclin A coloured as previous). The same site is presented for (b) cyclin D1 (PDB 2W96, coloured
as previous) and (c) cyclin T (PDB 4OGR, coloured as previous), which is known to accommodate the binding of both AFF4 and Tat.
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of CDK or cyclin family proteins or genetic deletion of
their regulators (e.g. the INK4 family for CDK4/6 [27]). In
addition to genetic amplification, structural alterations
through point mutation are also evident and may be relevant
to the subcellular function of these enzymes within the
cancer microenvironment.
Mutation of CDK4 R24 to C/H/L/S, first described in
melanoma [244–246], and documented in a further 27
samples in the cBioPortal database [247,248], is known to
increase kinase activity (reviewed in [249]). R24 is located
on b2 of the N-terminal lobe of CDK4 and abolishes binding
to p16INK4A [139,250]. The corresponding arginine in CDK6,
R31, coordinates through hydrogen bonds to several
p16INK4a polar/acidic residue side chains, namely D74,
T79 and D84, which may, in turn, be stabilized by R87 of
p16INK4A ([148], PDB 1BI7) (figure 11). As the sequences
of CDKs 4 and 6 are highly conserved within the N-terminal
lobe, it is anticipated that mutation of CDK4 R24 alsoabolishes p16INK4A association by breaking these key inter-
actions, although this hypothesis is yet to be confirmed by
determination of a CDK4–p16INK4A structure. That this
interaction is vital to CDK4/6–p16INK4a association is con-
firmed by reciprocal mutations to D84 in p16INK4a, one of
several proposed mutational hotspots [251]. Mutation
drives aberrant activation of CDK4/6–cyclin D [252]. The
p16INK4a D84N mutant shows a stark increase in CDK4
activity relative to WTp16INK4a in an Rb phosphorylation
assay [253], and limited ability to bind to CDKs 4 and 6 in
cell-free biochemical direct binding analyses [78].
Consultation of cancer genome repositories such as
cBioPortal [247,248], the COSMIC database [254] and Tumor-
Portal [255] reveals a variety of other missense mutations
within CDK–cyclins in the context of cancer (e.g. R168C in
CDK5, R86Q CDK9, R378G in cyclin A2). However, a
number of these are insufficiently characterized (mutations
reviewed in [256]). In a number of cases, this results from
the mutations being located outside of structured or
D108
T79
D74
D84
R31–CDK6 
R24–CDK4 
CDK6
p16INK4A
P48
H98
P114 H83
Figure 11. Point mutations in CDK4/6–p16INK4A. CDK4/6 and p16INK4A (represented here by CDK6, PDB 1BI7, CDK6, cyan; p16INK4A, gold) contain a number of
residues that are frequently mutated in cancer. Several commonly described mutations occur on the CDK–p16INK4A interface, disrupting the complex and leading to
kinase dysregulation. Other p16INK4A residues such as H98 and P48 are located further from the CDK-binding interface. CDK6 mutations are selected from those
described in cancer genome repositories (see the text for further details).
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difficult to interrogate biophysically/biochemically, while in
other instances it is amplification/upregulation of the
CDK–cyclin component rather than mutation that is likely
to drive proliferation.
Aside from mutations to key binding-partner interaction
sites, other aberrant processing of transcripts can also lead
to impaired cellular function of CDK–cyclins. In several
tumour types, the A/G870 polymorphism within the
CCND1 transcript can result in alternate splicing [257].
A/G870 is located at the end of exon 4 before intron 4
within the 5-exon long CCND1 DNA sequence. The A870
polymorphism is reportedly more likely to lead to an alterna-
tive CCND1 transcript, which in turn codes for the translation
of cyclin D1b protein [258,259]. Cyclin D1b includes
additional residues encoded by intron 4 and thus is bereft
of key regulatory residues at the C-terminal end [257,260].
These residues include the PEST motif (named using the
single letter amino acid code) and T286, important for protein
degradation and nuclear export, respectively [260], as well as
the LXXLL motif that is involved in cyclin D transcriptional
function [257]. As noted above, this region is flexible or
unstructured and not visible in the CDK4–cyclin D3 electron
density map. Mutations to equivalent residues in cyclin D2
(T280) and cyclin D3 (T283) have also been reported for a
small subset of acute myeloid leukaemia [261] and Burkitt
lymphoma [262] sufferers, respectively. Indeed, these
mutated proteins present with similar phenotypes to cyclin
D1b expressing cells, showing adverse degradation and
enhanced nuclear localization [261–264].
In addition to DNA mutations in CDK–cyclin partners,
aberrant post-translational processing is strongly linked to
dysregulated function. One particular example in the context
of cancer are the low-molecular-weight forms of cyclin E1,
though interestingly not cyclin E2 [265,266]. Cleaved post-
translationally by elastase [267], low-molecular-weight
forms of cyclin E1 facilitate increased kinase activity,
potentially through increased CDK2 affinity [267,268]. The
low-molecular-weight forms are cleaved within the sequence
N-terminal to the known structured CBFs, and thus, any
structural rationale for differences in affinity for CDK2 betweenfull-length and low-molecular-weight forms remains to be elu-
cidated. Whether cyclin E1 also contains additional N-terminal
regulatory motifs, reminiscent of those seen in cyclins A and B
such as the ABBA [167] or D-box [269] motifs, and whether
these sequences are lost in low-molecular-weight forms
remain to be confirmed.6. Macromolecular CDK-containing
complexes and electron microscopy:
the future
While an enormous wealth of detail has been revealed by
X-ray crystallography studies, the question of how CDK–
cyclin partners participate in larger macromolecular com-
plexes is yet to be fully answered. However, cryo-electron
microscopy (cryo-EM) is emerging as a technique that can
address this deficit, and several CDK–cyclin-containing
complexes have been determined.
Transcription factor IIH (TFIIH) is a large 10 subunit com-
plex recruited by RNA polymerase II (RNA pol II) during
transcription initiation and is also important in nucleotide
excision repair (NER) [6,270]. The CAK complex of CDK7–
cyclin H and Mat1 is known to be required for phosphoryl-
ation of RNA pol II CTD, but is removed from TFIIH
during NER [271,272]. However, the binding of CDK7–
cyclin H to Mat1 is not fully resolved within the TFIIH struc-
ture [273], which may reflect the ability of CAK to disengage
from TFIIH. The extended helical structure of Mat1 links the
TFIIH ATPase and helicase subunits XPD and XPB [273].
TFIIH is also regulated by another CDK-containing com-
plex, termed the Mediator complex [274]. The Mediator
complex contains approximately 30 polypeptide chains and
has a molecular weight of greater than 1 MDa. It is formed
from four distinct modules: the head, middle and tail mod-
ules, and the reversibly bound CDK8 kinase module
(CKM), which can contain CDK8 or CDK19 bound to
cyclin C [275–277]. CDK8–cyclin C inhibits RNA pol II
CTD phosphorylation by TFIIH through phosphorylation of
cyclin H at the extreme N- and C-terminal helices (on
Hsp90
Hsp90
CDK4
C-terminal lobe
Cdc37
CDK4
N-terminal lobe
Figure 12. The cryo-EM structure of the CDK4–Cdc37–Hsp90 complex. Both
copies of Hsp90 are coloured blue; Cdc37 is drawn in red and CDK4 in orange.
Structure is drawn from PDB 5FWK.
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structure of the yeast CKM revealed that cyclin C, and
not CDK8, binds to subunit MED12. The importance of
this interaction is highlighted by mutations to the cyclin
C–MED12-binding interface that inhibit Mediator activity
and have been linked to uterine leiomyoma [278]. MED12
bridges CDK8–cyclin C with MED13, which in turn associ-
ates with MED19 of the middle module. CDK8 is shown
to associate with the head module around subunits
MED18–20 [279]. The central modules of Mediator have
been revealed recently in a cryo-EM determined structure at
4.4 A˚ resolution [276,280].
Inactive kinase conformations within larger complexes
can also regulate function. An example of this phenomenon
is offered by CDK4 and the Hsp90 chaperone system [79].
Hsp90 protein kinase clients are selectively recruited through
the co-chaperone Cdc37 to form a complex that holds the
kinase in a protected state until it can be relinquished to an
appropriate partner [281–283]. Indeed, in the cryo-EM struc-
ture of the Hsp90–Cdc37–CDK4 complex (figure 12), CDK4
is partially unfolded at the N-terminus, where b5 of CDK4
has lost secondary structure and winds into Hsp90 [79].
Cdc37 also supports CDK4 at the C-terminal lobe between
the aC-helix and the loop linking to b4. CDK4 is a stronger
Cdc37–Hsp90 client than CDK6 [76], and this is reflected inthe ease with which the CDK can be handed off to partner
proteins such as the D-type cyclins and members of the
INK4 family [78].7. Concluding remarks
The expansion of the CDK family from a single essential
CDK in lower eukaryotes has enabled individual CDKs to
develop tissue-specific functions and to respond more sensi-
tively and selectively to intra- and intercellular signals.
Structural studies have revealed their distinguishing features
and help to provide explanations for their mechanistic differ-
ences. CDK–cyclin complexes have proved to be more diverse
than was originally envisaged. This structural diversity has
recently been successfully exploited to identify the first CDK
inhibitors to be registered for clinical use targeting CDK4
and CDK6 (reviewed in [32,72]). ATP-competitive CDK
inhibitors that selectively target other family members simi-
larly exploit sequence differences within the active site and/
or unique conformations that permit optimization of inhibi-
tor–CDK interactions that discriminate the family members.
Whether these inhibitors will be useful in the clinic will
require careful target validation studies to identify cellular
settings in which aberrant CDK activity is the cancer driver.
For the future, more specific chemical probes and selec-
tive antibodies are now required to provide greater
understanding of CDK roles outside of the cell cycle, in par-
ticular understanding the links between their roles
controlling the cell cycle and cell differentiation. Another
exciting development is the application of electron
microscopy to study larger CDK-containing complexes.
These structures will further our understanding of CDK regu-
lation and may well provide additional opportunities to more
selectively inhibit CDK activity in clinically relevant settings.
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